CN107029040B - Compound traditional Chinese medicine powder for treating cow subclinical mastitis - Google Patents

Compound traditional Chinese medicine powder for treating cow subclinical mastitis Download PDF

Info

Publication number
CN107029040B
CN107029040B CN201710300048.8A CN201710300048A CN107029040B CN 107029040 B CN107029040 B CN 107029040B CN 201710300048 A CN201710300048 A CN 201710300048A CN 107029040 B CN107029040 B CN 107029040B
Authority
CN
China
Prior art keywords
parts
herb
group
chinese medicine
traditional chinese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710300048.8A
Other languages
Chinese (zh)
Other versions
CN107029040A (en
Inventor
王水莲
邓子立
段洪峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunan Agricultural University
Original Assignee
Hunan Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunan Agricultural University filed Critical Hunan Agricultural University
Priority to CN201710300048.8A priority Critical patent/CN107029040B/en
Publication of CN107029040A publication Critical patent/CN107029040A/en
Application granted granted Critical
Publication of CN107029040B publication Critical patent/CN107029040B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/78—Saururaceae (Lizard's-tail family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739—Sanguisorba (burnet)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A compound traditional Chinese medicine powder for treating cow subclinical mastitis is a powder prepared from the following raw materials in parts by weight: 8-10 parts of giant knotweed, 8-10 parts of garden burnet, 6-8 parts of cyrtomium rhizome, 8-10 parts of barbed skullcap herb, 8-10 parts of dandelion, 8-10 parts of Chinese pulsatilla root, 8-10 parts of hawthorn, 8-10 parts of Chinese thorowax root, 8-10 parts of hairyvein agrimonia herb and bud, 8-10 parts of Chinese loropetalum leaf, 8-10 parts of perfoliate knotweed herb, 8-10 parts of heartleaf houttuynia herb, 8-10 parts of concha ostreae, 8-10 parts of phyllanthus urinaria, 8-10 parts of humifuse euphorbia herb, 2-4 parts of motherwort herb and 4-6 parts of cowherb seed. The traditional Chinese medicine composition is used for treating the recessive mastitis of the dairy cows, and has the characteristics of high treatment rate, good anti-inflammation performance, safety, no toxic or side effect and the like.

Description

Compound traditional Chinese medicine powder for treating cow subclinical mastitis
Technical Field
The invention relates to a compound traditional Chinese medicine powder for treating cow subclinical mastitis.
Background
Mastitis, also known as mastitis, is caused by local blood circulation disorder of breast, which causes low immunity, and can not resist invasion of external pathogenic microorganisms, or mammary parenchyma or interstitial inflammation caused by mechanical injury, and is commonly found in cows in postpartum lactation, especially in cows in lactation. The traditional Chinese veterinary medicine considers that mastitis, namely yellow milk, breast swelling and acute mastitis, is inflammation caused by dampness, phlegm, qi and blood stagnation without dispersing, and is related to liver and stomach meridians.
The mastitis of the dairy cow can reduce the yield and the quality of the milk, so that the cow is eliminated in advance, and the mastitis is one of important factors for restricting the development of the dairy industry and causes great economic loss for the development of the dairy industry. At present, antibiotic therapy is mostly adopted for treating cow mastitis, but the large amount of antibiotic can cause the generation of drug-resistant strains and the elimination of sensitive bacteria, and the drug-resistant strains and the bacteria gradually take the mainstream, thereby causing the change of the pathogenic bacteria group of the mastitis.
The Chinese medicine theory has a thousand years history, which has great advantages for domestic research and utilization of Chinese medicine for preventing and treating mastitis. The traditional Chinese medicine belongs to a natural product, contains various drug effects or nutritional ingredients, has the advantages of antibiosis, antiphlogosis, low toxicity, no residue or low residue and the like in part, has the characteristic of prevention before the use under the guidance of the traditional veterinarian theory, and lays a foundation for preparing the traditional Chinese medicine preparation for treating the recessive mastitis of the dairy cows.
Disclosure of Invention
The invention aims to solve the problems and provides a compound traditional Chinese medicine powder capable of effectively treating the recessive mastitis of the dairy cows.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows: a compound traditional Chinese medicine powder for treating cow subclinical mastitis is a powder prepared from the following raw materials in parts by weight: 8-10 parts of giant knotweed, 8-10 parts of garden burnet, 6-8 parts of cyrtomium rhizome, 8-10 parts of barbed skullcap herb, 8-10 parts of dandelion, 8-10 parts of Chinese pulsatilla root, 8-10 parts of hawthorn, 8-10 parts of Chinese thorowax root, 8-10 parts of hairyvein agrimonia herb and bud, 8-10 parts of Chinese loropetalum leaf, 8-10 parts of perfoliate knotweed herb, 8-10 parts of heartleaf houttuynia herb, 8-10 parts of concha ostreae, 8-10 parts of phyllanthus urinaria, 8-10 parts of humifuse euphorbia herb, 2-4 parts of motherwort herb and 4-6 parts of cowherb seed.
Preferably, the compound traditional Chinese medicine powder is powder prepared from the following raw materials in parts by weight: 9-10 parts of giant knotweed, 9-10 parts of garden burnet, 7-8 parts of cyrtomium rhizome, 9-10 parts of barbed skullcap herb, 9-10 parts of dandelion, 9-10 parts of Chinese pulsatilla root, 9-10 parts of hawthorn, 9-10 parts of radix bupleuri, 9-10 parts of hairyvein agrimonia herb and bud, 9-10 parts of loropetalum chinense leaf, 9-10 parts of perfoliate knotweed herb, 9-10 parts of heartleaf houttuynia herb, 9-10 parts of concha ostreae, 9-10 parts of phyllanthus urinaria, 9-10 parts of humifuse euphorbia herb, 3-4 parts of motherwort herb and 5-6 parts of cowherb seed.
Preferably, the compound traditional Chinese medicine powder is powder prepared from the following raw materials in parts by weight: 10 parts of giant knotweed, 10 parts of garden burnet, 8 parts of cyrtomium rhizome, 10 parts of barbed skullcap herb, 10 parts of dandelion, 10 parts of Chinese pulsatilla root, 10 parts of hawthorn, 10 parts of radix bupleuri, 10 parts of hairyvein agrimonia herb and bud, 10 parts of loropetalum chinense leaf, 10 parts of perfoliate knotweed herb, 10 parts of heartleaf houttuynia herb, 10 parts of concha haliotidis, 10 parts of phyllanthus urinaria, 10 parts of humifuse euphorbia herb, 4 parts of motherwort herb and 6 parts of cowherb seed.
The traditional Chinese medicine components of the invention comprise dandelion, giant knotweed, barbed skullcap herb, radix bupleuri, perfoliate knotweed herb, heartleaf houttuynia herb and phyllanthus urinaria which are main medicines for clearing away heat and toxic material, resisting bacteria and diminishing inflammation, the garden burnet root, cyrtomium rhizome, hairyvein agrimonia herb and bud, clam shell, Chinese pulsatilla root and loropetalum chinense leaf are auxiliary medicines for stopping bleeding and relieving pain, resisting inflammation and diminishing swelling, the hawthorn can invigorate spleen and stimulate the appetite, and promote digestion and remove stagnation, and the motherwort herb and humifuse euphorbia herb are used for activating blood and dissolving stasis after delivery, and are matched with the effects. The traditional Chinese medicines in the formula are combined to play the effects of clearing away heat and toxic materials, resisting bacteria and diminishing inflammation, promoting blood circulation to remove blood stasis, promoting lactation to reduce swelling and improving the immunity and disease resistance of the organism.
The compound traditional Chinese medicine powder is suitable for treating recessive mastitis of dairy cows, and is convenient to use and prepared into powder. The compound traditional Chinese medicine powder is prepared by crushing and uniformly mixing the traditional Chinese medicine components according to the parts by weight.
The traditional Chinese medicine powder is convenient to use, can be mixed in feed for free ingestion or irrigation with water, each cow (with the weight of 400-500KG) takes 200-300g each time, 1 time each day, and 8 days as a treatment course.
The compound traditional Chinese medicine powder can enhance the oxidation resistance of the dairy cow, reduce the number of somatic cells in milk and has obvious treatment effect on recessive mastitis. The specific test process is as follows:
the tested Holstein cows (including sick and healthy cows) were from a cow farm with an average weight of 400-500KG, and the sick cows were found to have higher somatic cell count than the healthy cows by somatic cell examination and had no clinical symptoms without treatment. Selecting 20 concealed type mastitis cows, and feeding 200g of the compound traditional Chinese medicine powder mixed feed for 1 time/d, and taking 8d as group A; selecting 20 concealed type mastitis cows, 300g of the compound traditional Chinese medicine powder mixed feed of the invention, and feeding for 1 time/d, and 8d for continuous use to obtain group B; selecting 20 cattle with latent mastitis but without treatment as group C; 20 healthy cows were selected as group D (both groups C and D were not treated). Feeding 4 groups of cattle with the same feed and drinking water under the same feeding environment condition, respectively feeding 0d, 4d and 8d, respectively collecting 10 mL/head of blood of each test cattle from the jugular vein of the cow by using a 30mL injector, standing for separating out serum, centrifuging (3500rpm, 15min), sucking the serum out of a centrifuge tube (indicating date, cow number and breast area), and storing in a 0-4 ℃ refrigerator. Detecting the activities of SOD and GSH-PX in A, B, C and D group serum and the contents of MDA and NO; somatic data were examined for A, B and group C before and after dosing.
1. Influence of compound Chinese medicinal powder on SOD, GSH-PX, MDA and NO in milk cow serum
As can be seen from Table 1, the SOD content in the A, B groups was not significantly different from that in the C group (P >0.05) and significantly different from that in the D group (P <0.05) when the medicines were used 0D. The SOD content of the drug-treated 4d and A, B groups is not obviously different from that of the C, D group (P is more than 0.05). When the medicine is used for 8D, the SOD content of the group A is not obviously different from that of the group C (P is more than 0.05), and is obviously different from that of the group D (P is less than 0.05); the SOD content of group B is obviously different from that of group C (P <0.05) and is not obviously different from that of group D (P > 0.05).
TABLE 1 change in SOD in serum before and after drug administration
Grouping 0d 4d 8d
Group A 35.59±14.71a 42.95±6.54a 43.33±4.03a
Group B 33.51±4.29a 39.73±4.49a 54.18±11.70b
Group C 41.98±4.43a 41.7±8.20a 38.71±7.71a
Group D 58.97±5.82b 51.79±12.73ab 59.24±8.47b
Note: in the comparison in each column in the table above, the lower case letters are not identical to indicate significant difference (P <0.05), and the lower case letters are identical to indicate insignificant difference (P > 0.05); different capitalized letters indicate significant difference (P <0.01), the same capitalized letters indicate insignificant difference (P > 0.05). The same applies below.
As can be seen from Table 2, the MDA content in A, B group was not significantly different from that in C group (P >0.05) and was significantly different from that in D group (P <0.01) with drug 0D. The MDA content of the drug-applied 4d, A, B group is not significantly different from that of the C, D group (P > 0.05). In the application 8D, the MDA content of A, B groups is different from that of the C group (P <0.05) and is not different from that of the D group (P > 0.05).
TABLE 2 MDA Change in serum before and after drug administration
Grouping 0d 4d 8d
Group A 3.94±0.87Aa 3.3±0.70a 2.23±0.59a
Group B 4.02±0.85Aa 3.33±0.71a 2.01±1.01a
Group C 3.23±0.93b 3.26±0.74a 3.44±0.66b
Group D 2.59±0.68B 2.65±0.73a 2.65±0.88a
As shown in Table 3 below, the GSH-PX content in the drug 0D, A, B group was not significantly different from the group C (P >0.05) and significantly different from the group D (P < 0.05). The GSH-PX content of the drug 4D and A, B groups is obviously different from that of the C group (P <0.05) and is not obviously different from that of the D group (P < 0.05). The GSH-PX content in the group A is obviously different from that in the group C (P <0.05) and is not obviously different from that in the group D (P >0.05) when the medicine is used for 8D; the content of GSH-PX in the group B is remarkably different from that in the group C (P <0.05) and is not remarkably different from that in the group D (P > 0.05).
TABLE 3 changes in serum GSH-PX before and after drug administration
Grouping 0d 4d 8d
Group A 164.01±34.90a 180.27±31.90a 198.73±21.98a
Group B 167.68±46.44b 200.88±59.82a 236.58±32.70a
Group C 152.69±45.42a 149.19±52.84b 150.79±33.87c
Group D 220.51±22.60c 234.73±21.31a 244.06±43.44a
As shown in Table 4 below, the NO content in A, B group with 0D drug was not significantly different from that in C group (P >0.05) and was significantly different from that in D group (P < 0.01). The NO content of the A, B group with the drug 4D is very different from that of the C group (P <0.01) and is not different from that of the D group (P < 0.05). When the medicine is used for 8D, the NO content of the group A is obviously different from that of the group C (P <0.05) and is not obviously different from that of the group D (P > 0.05); the NO content of the group B is very different from that of the group C (P <0.01) and is not significant from that of the group D (P > 0.05).
TABLE 4 NO Change before and after drug administration
Figure BDA0001283691640000041
Figure BDA0001283691640000051
2. The influence of the compound traditional Chinese medicine powder on the number of somatic cells in milk
The number of somatic cells before and after each group was administered is shown in Table 5. As can be seen from Table 5, the average number of somatic cells in group A decreased to about 50 ten thousand, the number of somatic cells in group B decreased to about 30 ten thousand, and the number of somatic cells in group C increased instead of the number of somatic cells in the drug-free blank group after one treatment course. The invention can reduce the number of somatic cells in milk and achieve the effect of treating the recessive mastitis of the dairy cows.
TABLE 5 somatic cell count before and after drug administration
Grouping Before administration After administration
Group A 89.50±30.05 53.50±19.41
Group B 108±33.38 31.33±12.29
Group C 88.50±34.52 115.50±49.35
3. Clinical treatment effect of compound traditional Chinese medicine powder
The treatment effects before and after administration of each group are shown in Table 6. As can be seen from table 6, the cure rate was 50% (10/20) in group a and 85% (17/20) in group B. The clinical treatment effect of the invention on the cow subclinical mastitis is obvious.
TABLE 6 clinical therapeutic effect of the compound Chinese herbal medicine powder
Grouping Cure rate Is effective Invalidation
Group A 50％(10/20) 65％(13/20) 35％(7/20)
Group B 85％(17/20) 85％(17/20) 15％(3/20)
Note: in the table, the value range of the somatic cells is less than 30 ten thousand/mL, which is 'cured'; <50 ten thousand/mL is "effective"; >50 ten thousand/mL is "invalid".
When the organism is in an inflammation period, the cow body can generate an antibacterial reaction, when bacteria are killed by aggregated white blood cells, a large amount of oxygen free radicals appear, excessive free radicals can be accumulated in the body and attack biological membranes, the activities of SOD and GSH-PX in serum are obviously reduced, and the contents of MDA and NO are obviously increased. The somatic cells in milk of dairy cows are mainly leucocytes and damaged and exfoliated mammary epithelial cells, and the number of the somatic cells is in direct proportion to the severity of the disease condition, so that the number of the somatic cells is an important index for judging whether the dairy cows suffer from mastitis, particularly recessive mastitis. The compound traditional Chinese medicine can enhance the oxidation resistance of the dairy cow, reduce the number of somatic cells in milk and reduce the prevalence rate of mastitis.
Whether the comparison of the differences of the antioxidant indexes between the administration 0D, 4D and 8D of the A, B two dose groups or the comparison between the A, B group and the blank group C and the healthy group D shows that the 300g dose has a significant or extremely significant effect on the antioxidant indexes of the cattle, particularly the MDA content is lower than that of the healthy group D. Meanwhile, the compound Chinese herbal medicine powder has obvious treatment effect on the cow subclinical mastitis, and particularly, when the dose of 300g is used, the clinical treatment effect on the cow subclinical mastitis can reach 85%.
The compound traditional Chinese medicine powder for treating the cow subclinical mastitis is prepared by screening according to the compatibility principle of the traditional Chinese medicine and the theories of modern epidemiology and etiology on the basis of practical application, is used for treating the cow subclinical mastitis, and has the advantages of good effect, good anti-inflammation property, safety, no toxic or side effect and convenient administration.
Detailed Description
The present invention is further illustrated by the following specific examples.
Example 1
The compound traditional Chinese medicine powder is prepared by crushing and uniformly mixing 8 parts by weight of giant knotweed rhizome, 8 parts by weight of garden burnet root, 6 parts by weight of cyrtomium rhizome, 8 parts by weight of barbed skullcap herb, 8 parts by weight of dandelion, 8 parts by weight of Chinese pulsatilla root, 8 parts by weight of hawthorn, 8 parts by weight of radix bupleuri, 8 parts by weight of hairyvein agrimony, 8 parts by weight of loropetalum chinense leaf, 8 parts by weight of perfoliate knotweed herb, 8 parts by weight of heartleaf houttuynia herb, 8 parts by weight of concha haliotidis, 8 parts by weight of phyllanthus urinaria, 8 parts by.
Example 2
The compound traditional Chinese medicine powder is prepared by crushing and uniformly mixing 10 parts by weight of giant knotweed, 10 parts by weight of garden burnet, 8 parts by weight of cyrtomium fortunei, 10 parts by weight of barbed skullcap herb, 10 parts by weight of dandelion, 10 parts by weight of Chinese pulsatilla root, 10 parts by weight of hawthorn, 10 parts by weight of radix bupleuri, 10 parts by weight of hairyvein agrimony, 10 parts by weight of loropetalum chinense leaf, 10 parts by weight of perfoliate knotweed herb, 10 parts by weight of houttuynia cordata, 10 parts by weight of concha haliotidis, 10 parts by weight of phyllanthus urinaria, 10 parts by.
Example 3
Respectively taking 9 parts of giant knotweed, 9 parts of garden burnet, 7 parts of cyrtomium rhizome, 9 parts of barbed skullcap herb, 9 parts of dandelion, 9 parts of Chinese pulsatilla root, 9 parts of hawthorn, 9 parts of radix bupleuri, 9 parts of hairyvein agrimony, 9 parts of loropetalum chinense leaf, 9 parts of perfoliate knotweed herb, 9 parts of heartleaf houttuynia herb, 9 parts of concha haliotidis, 9 parts of phyllanthus urinaria, 9 parts of humifuse euphorbia herb, 3 parts of motherwort and 5 parts of cowherb seed according to the parts by weight, crushing and uniformly mixing to obtain the compound traditional Chinese medicine powder.

Claims (3)

1. The compound traditional Chinese medicine powder for treating the recessive mastitis of the dairy cow is characterized by being powder prepared from the following raw materials in parts by weight: 8-10 parts of giant knotweed, 8-10 parts of garden burnet, 6-8 parts of cyrtomium rhizome, 8-10 parts of barbed skullcap herb, 8-10 parts of dandelion, 8-10 parts of Chinese pulsatilla root, 8-10 parts of hawthorn, 8-10 parts of Chinese thorowax root, 8-10 parts of hairyvein agrimonia herb and bud, 8-10 parts of Chinese loropetalum leaf, 8-10 parts of perfoliate knotweed herb, 8-10 parts of heartleaf houttuynia herb, 8-10 parts of concha ostreae, 8-10 parts of phyllanthus urinaria, 8-10 parts of humifuse euphorbia herb, 2-4 parts of motherwort herb and 4-6 parts of cowherb seed.
2. The compound traditional Chinese medicine powder for treating cow subclinical mastitis according to claim 1, which is a powder prepared from the following raw materials in parts by weight: 9-10 parts of giant knotweed, 9-10 parts of garden burnet, 7-8 parts of cyrtomium rhizome, 9-10 parts of barbed skullcap herb, 9-10 parts of dandelion, 9-10 parts of Chinese pulsatilla root, 9-10 parts of hawthorn, 9-10 parts of radix bupleuri, 9-10 parts of hairyvein agrimonia herb and bud, 9-10 parts of loropetalum chinense leaf, 9-10 parts of perfoliate knotweed herb, 9-10 parts of heartleaf houttuynia herb, 9-10 parts of concha ostreae, 9-10 parts of phyllanthus urinaria, 9-10 parts of humifuse euphorbia herb, 3-4 parts of motherwort herb and 5-6 parts of cowherb seed.
3. The compound traditional Chinese medicine powder for treating cow subclinical mastitis according to claim 2, which is a powder prepared from the following raw materials in parts by weight: 10 parts of giant knotweed, 10 parts of garden burnet, 8 parts of cyrtomium rhizome, 10 parts of barbed skullcap herb, 10 parts of dandelion, 10 parts of Chinese pulsatilla root, 10 parts of hawthorn, 10 parts of radix bupleuri, 10 parts of hairyvein agrimonia herb and bud, 10 parts of loropetalum chinense leaf, 10 parts of perfoliate knotweed herb, 10 parts of heartleaf houttuynia herb, 10 parts of concha haliotidis, 10 parts of phyllanthus urinaria, 10 parts of humifuse euphorbia herb, 4 parts of motherwort herb and 6 parts of cowherb seed.
CN201710300048.8A 2017-05-02 2017-05-02 Compound traditional Chinese medicine powder for treating cow subclinical mastitis Active CN107029040B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710300048.8A CN107029040B (en) 2017-05-02 2017-05-02 Compound traditional Chinese medicine powder for treating cow subclinical mastitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710300048.8A CN107029040B (en) 2017-05-02 2017-05-02 Compound traditional Chinese medicine powder for treating cow subclinical mastitis

Publications (2)

Publication Number Publication Date
CN107029040A CN107029040A (en) 2017-08-11
CN107029040B true CN107029040B (en) 2020-06-16

Family

ID=59538433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710300048.8A Active CN107029040B (en) 2017-05-02 2017-05-02 Compound traditional Chinese medicine powder for treating cow subclinical mastitis

Country Status (1)

Country Link
CN (1) CN107029040B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110090222B (en) * 2018-01-31 2022-04-05 广西英路维特药物有限公司 Application of pulsatilla chinensis extract in preparation of medicines for treating viral and/or bacterial diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104161176A (en) * 2013-07-15 2014-11-26 河南联合英伟饲料有限公司 Traditional Chinese medicine feed additive for effectively preventing dairy cow mastitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104161176A (en) * 2013-07-15 2014-11-26 河南联合英伟饲料有限公司 Traditional Chinese medicine feed additive for effectively preventing dairy cow mastitis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
中西药结合治疗奶牛隐性乳房炎;杨利军;《中兽医学杂志》;20031231(第06期);第12页 *
消炎泌乳冲剂对隐性乳房炎奶牛血清自由基代谢的影响;金兰梅等;《中国兽医杂志》;20101231;第46卷(第12期);第59-61页 *

Also Published As

Publication number Publication date
CN107029040A (en) 2017-08-11

Similar Documents

Publication Publication Date Title
CN102836367B (en) Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof
CN104491203A (en) Chinese herbal medicine fermentative extract liquid for preventing and treating cow mastitis and preparation method of Chinese herbal medicine fermentative extract liquid
CN102225127B (en) Traditional Chinese medicine composite for treating mastitis of dairy cattle
CN102579597B (en) Chinese herbal compound prescription for preventing and curing mammitis of mammalian livestock and method for preparing same
CN107029040B (en) Compound traditional Chinese medicine powder for treating cow subclinical mastitis
CN105726631A (en) Application of officinal magnolia bark extract to prepare medicine for treating cow mastitis
CN104367746A (en) Compound traditional Chinese medicine perfusion agent used for treating endometritis of dairy cow and preparation method of compound traditional Chinese medicine perfusion agent
CN108096355B (en) Traditional Chinese medicine compound formula for treating cold-dampness type diarrhea of pigs, preparation and application
CN104491222B (en) A kind of Chinese medicine for treating ox follicular cyst and preparation method thereof
CN109432287B (en) Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof
CN109646546B (en) A Chinese medicinal composition for preventing and treating diarrhea of livestock, and its preparation method
CN102670793A (en) Chinese herba preparation for increasing cow immunity and reducing milk somatic number and preparation method
CN107281354B (en) Natural pharmaceutical composition for treating clinical cow mastitis and preparation method thereof
CN105687315A (en) Traditional Chinese medicine perfusion agent preventing and treating dairy cow mastitis and preparation method thereof
CN111358853A (en) Chinese herbal medicine preparation for treating chlamydiosis of livestock and poultry as well as preparation and application thereof
CN113876853B (en) Medicine for preventing and treating cow mastitis disease and preparation method and application thereof
CN114099573B (en) Traditional Chinese medicine composition for improving egg laying performance of laying hens as well as preparation method and application of traditional Chinese medicine composition
CN115721677B (en) Traditional Chinese medicine composition for preventing and treating calf bacterial diarrhea, and preparation method and application thereof
CN113813306B (en) Traditional Chinese medicine composition for preventing and treating infectious rhinitis of chicken
CN107582650A (en) A kind of Chinese medicine composition for being used to prevent and treat sow mastitis
CN103893259A (en) Novel traditional Chinese medicine composition for controlling recessive mastitis and preparation method thereof
CN107951972A (en) Apply medicinal lotion or ointment outside a kind of Chinese traditional medicine composition for treating mastitis for milk cows thing and preparation method thereof
CN109125427B (en) Penyanjing suppository and preparation method thereof
CN104922313A (en) Pharmaceutical composition for treating dairy cattle mastitis
CN116509969A (en) Traditional Chinese medicine composition for treating cow clinical type mastitis and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant